$12 Billion in One Day: What Biogen and Lilly Deals Signal
On March 31 2026, Biogen acquired Apellis for $5.6B and Eli Lilly acquired Centessa for up to $7.8B on the same day. Both deals target mid-stage assets and include contingent value rights. For biotech operators this signals accelerating pipeline pressure and shrinking commercial planning windows.
$12 Billion in One Day: What Biogen and Lilly Deals Signal Read More »